Abstract
Nimodipine is an L-type calcium channel blocker and is used to treat vasospasm in patients with subarachnoid hemorrhage. Its putative mechanism of action is relaxation of smooth muscle cells in cerebral arteries. In addition, nimodipine may have pleiotropic effects against vasospasm. Systemic hypotension is an adverse effect when patients are treated with oral or intravenous nimodipine. Intracranial administration of nimodipine formulations may produce higher concentration of nimodipine in the cerebrospinal fluid (CSF) than is possible to achieve orally or intravenously, while resulting in lower incidence of systemic hypotension. The aim of this study was to provide information on plasma and CSF levels of nimodipine in beagle dogs as a comparative data for development of experimental intracranial treatment modalities. Plasma levels of nimodipine were measured after current 30 and 60 mg single oral dose of nimodipine (Nimotop® 30 mg tablets), a single intravenous bolus 0.72 mg/dog of nimodipine (Nimotop® 0.2 mg/ml infusion solution) and CSF levels after 60 mg single oral dose of nimodipine. CSF/Plasma concentration ratio of nimodipine after oral administration of 60 mg at 1 h was 0.013 ± 0.0005. The mean terminal elimination half-life of nimodipine after i.v. bolus dose 0.72 mg was 1.8 h and mean plasma clearance was 40.3 and 3.4 l/h/kg. Absolute bioavailability was 22 %. Maximum plasma concentration and area under the plasma concentration–time curve from time of administration until the last measurable plasma concentration increased in a dose-proportional manner comparing the exposure parameters at oral doses of 30 and 60 mg. Individual variation in the kinetic profile of nimodipine was measured.
Similar content being viewed by others
References
Alborch E, Salom JB, Torregrosa G (1995) Calcium channels in cerebral arteries. Pharmacol Ther 68(1):1–34
Athar MK, Levine JM (2012) Treatment options for cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurotherapeutics 9(1):37–43
Barth M, Pena P, Seiz M et al (2011) Feasibility of intraventricular nicardipine prolonged release implants in patients following aneurysmal subarachnoid haemorrhage. Br J Neurosurg 25(6):677–683
Caner B, Hou J, Altay O, Fuj M, Zhang JH (2012) Transition of research focus from vasospasm to early brain injury after subarachnoid hemorrhage. J Neurochem 123(Suppl 2):12–21
Cook DJ, Kan S, Ai J, Kasuya H, Macdonald RL (2012) Cisternal sustained release dihydropyridines for subarachnoid hemorrhage. Curr Neurovasc Res 9(2):139–148
Dreier JP, Major S, Manning A et al (2009) Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 132(Pt 7):1866–1881
FDA (2005) Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf. Accessed July 2005
Hänggi D, Turowski B, Beseoglu K, Yong M, Steiger HJ (2008) Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion. AJNR Am J Neuroradiol 29(6):1053–1060
Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T (2005) Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery 56(5):895–902 (discussion 895–902)
Macdonald RL, Leung M, Tice T (2012) Intracranial drug delivery for subarachnoid hemorrhage. Ther Deliv 3(1):91–103
Pickard JD, Murray GD, Illingworth R et al (1989) Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 298(6674):636–642
Rämsch KD, Ahr G, Tettenborn D, Auer LM (1985) Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia (Stuttg) 28(Suppl 1):74–78
Richard S (2005) Vascular effects of calcium channel antagonists: new evidence. Drugs 65(Suppl 2):1–10
Rinne V, Scheinin M (2012a) Bioanalytical method for the determination of nimodipine in plasma by API 4000 LC-MS/MS. CRST/University of Turku, Method 238 v04, August 2012
Rinne V, Scheinin M (2012b) Bioanalytical method for the determination of nimodipine in spinal fluid by API 4000 LC-MS/MS. CRST/University of Turku, Method 240 v03, May 2012
Sehba FA, Hou J, Pluta RM, Zhang JH (2012) The importance of early brain injury after subarachnoid hemorrhage. Prog Neurobiol 97(1):14–37
Triggle DJ (2006) L-type calcium channels. Curr Pharm Des 12(4):443–457
Velat GJ, Kimball MM, Mocco JD, Hoh BL (2011) Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature. World Neurosurg 76(5):446–454
Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB (2008) Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28(11):1761–1770
Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL (2011) Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 31(7):1545–1553
Acknowledgments
The authors would like to thank the animal caregivers for their professional animal healthcare.
Conflict of interest
The study was funded by Orion Pharma Corporation and TEKES. Writing this paper was purely researcher driven and was supported by a research grant from the Maire Taponen foundation (J. K.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koskimäki, J., Tarkia, M., Ahtola-Sätilä, T. et al. Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. Eur J Drug Metab Pharmacokinet 41, 295–300 (2016). https://doi.org/10.1007/s13318-015-0258-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-015-0258-5